Skip to main content

Table 2 Multivariate analyses of independent significance of experimental intervention on clinical outcome

From: Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Variables OS(42/341) PFS(63/341) DMFS(49/341)
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gender (male vs female) 1.053 (0.546–2.031) 0.877 0.904 (0.518–1.578) 0.723 0.737 (0.384–1.412) 0.357
Age (≤50 vs >50) 2.039 (1.092–3.807) 0.025 1.512 (0.918–2.492) 0.105 1.342 (0.761–2.367) 0.310
Pathological type (WHO I-II vs WHO III) 2.295 (0.361–14.583) 0.379 1.961 (0.531–7.246) 0.313 1.532 (0.420–5.588) 0.518
T stage (T1-T2 vs T3-T4) 1.329 (0.944–1.870) 0.103 1.123 (0.866–1.457) 0.382 1.129 (0.838–1.520) 0.425
N stage (N0–1 vs N2–3) 1.766 (1.186–2.630) 0.005 1.378 (0.990–1.920) 0.058 1.634 (1.117–2.391) 0.011
Chemotherapy cycle (≤3 vs >3) 2.381 (0.910–6.226) 0.077 1.747 (0.830–3.676) 0.142 1.808 (0.767–4.264) 0.176
SUA level (≤327 vs >327) 2.385 (1.208–4.707) 0.012 1.658 (0.989–2.779) 0.055 1.744 (0.964–3.156) 0.066
Tumor response to IC (CR/PR vs SD/PD) 1.915 (1.044–3.648) 0.036 2.381 (1.408–3.816) 0.001 2.764 (1.554–4.851) 0.001
  1. Abbreviations: CI confidence interval, CR complete response, DMFS distant metastasis-free survival, HR hazard ratio, IC induction chemotherapy, OS overall survival, PD disease progression, PFS progression-free survival, PR partial response, SD stable disease, SUA serum uric acid